If you’re planning a health outcomes study in Germany, choosing between statutory and commercial claims data isn’t about which dataset […]
Does Your Research Question Demand Statutory or Commercial Data? Read Post ยป
Germany just unlocked access to decades of statutory health insurance data covering most of its population, but there’s a catch:
Germany’s Health Data Use Act & EHDS: Dual-Layer Policy Transformation Read Post ยป
Getting German health insurance claims data wrong at the start cascades through every downstream deliverable in your HEOR strategy. One
Statutory vs Commercial German Claims Data: Which Access Route Fits? Read Post ยป
If you’re planning research with German statutory health insurance data, there’s a critical structural break in 2019 that could invalidate
Data Model 3 Granularity Gains: Detail Improvements from 2019 Onwards Read Post ยป
Working with rare diseases in Germany? A single statistical insight might reshape how you think about data requirements: patients with
When Does 7.2M Patients Suffice for Rare Disease Research in German Data? Read Post ยป
Germany’s new Health Data Use Act promises researchers access to nationwide insurance claims data, but the application process has strict
How to Access German Claims Data Under GDNG: Application Process Read Post ยป
If you’re planning real-world evidence research in Germany, the size of your dataset might matter less than you think. When
FDZ Gesundheit vs Commercial Claims Data: Iterative Analysis Capability Read Post ยป
Germany has one of the most analytically valuable health data environments in Europe โ and one of the most structurally
When pharma market access directors ask me about the biggest gap in their evidence strategy, it’s almost always the same
Diagnosed Prevalence and Patient Data Solutions for Pharma Read Post ยป
If you’re leading market access, HEOR, or commercial analytics at a pharma or medtech company, you’ve probably hit this wall:
